Literature DB >> 28278701

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).

Elżbieta Iskierka-Jażdżewska1, Marek Hus2, Krzysztof Giannopoulos3, Elżbieta Mądro4, Jadwiga Hołojda5, Magdalena Piotrowska6, Jan M Zaucha7, Weronika Piszczek8, Agnieszka Szeremet9, Małgorzata Wojciechowska10, Paweł Steckiewicz11, Wanda Knopińska-Posłuszny12, Marek Osowiecki13, Joanna Drozd-Sokołowska14, Beata Kumiega15, Sławomira Kyrcz-Krzemień16, Janusz Hałka17, Marek Dudziński18, Paulina Wieszczy19, Tadeusz Robak1, Krzysztof Warzocha4, Krzysztof Jamroziak4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28278701     DOI： 10.1080/10428194.2017.1292353

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

1.  Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Authors:  Inhye E Ahn; Neil Basumallik; Xin Tian; Susan Soto; Adrian Wiestner
Journal:  Blood       Date:  2019-03-27       Impact factor: 22.113

2.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

3.  Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh
Journal:  Oncologist       Date:  2020-09-20

Review 4.  Ibrutinib dose modifications in the management of CLL.

Authors:  Camille Hardy-Abeloos; Rachel Pinotti; Janice Gabrilove
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

5.  Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.

Authors:  Peter Georgantopoulos; Huiying Yang; LeAnn B Norris; Charles L Bennett
Journal:  Cancer Med       Date:  2019-04-14       Impact factor: 4.452

6.  Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.

Authors:  Yanhua Zhou; Hongtao Lu; Meifeng Yang; Chenhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 7.  Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Authors:  Bartosz Puła; Aleksandra Gołos; Patryk Górniak; Krzysztof Jamroziak
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

Review 8.  Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.

Authors:  Thomas E Lew; Mary Ann Anderson; John F Seymour
Journal:  Cancer Drug Resist       Date:  2020-05-23

9.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Authors:  Lisa S Chen; Prithviraj Bose; Nichole D Cruz; Yongying Jiang; Qi Wu; Philip A Thompson; Shuju Feng; Michael H Kroll; Wei Qiao; Xuelin Huang; Nitin Jain; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2018-09-25       Impact factor: 25.476

10.  Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis.

Authors:  Elisabeth Nuttall; Joanna Tung; Ellie Trounce; Rosalynd Johnston; Timothy Chevassut
Journal:  J Blood Med       Date:  2019-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.